Electrocardiogram abnormalities with atazanavir and lopinavir/ritonavir.

about

Boosted protease inhibitors and the electrocardiographic measures of QT and PR durations

P2860

Q35034349-F5DAAB00-F316-42C7-9905-363409884788

P2860

Electrocardiogram abnormalities with atazanavir and lopinavir/ritonavir.

Item

http://www.wikidata.org/entity/Q43244207

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh-hant

name

Electrocardiogram abnormalities with atazanavir and lopinavir/ritonavir.

@en

Electrocardiogram abnormalities with atazanavir and lopinavir/ritonavir.

@nl

type

Item

label

Electrocardiogram abnormalities with atazanavir and lopinavir/ritonavir.

@en

Electrocardiogram abnormalities with atazanavir and lopinavir/ritonavir.

@nl

prefLabel

Electrocardiogram abnormalities with atazanavir and lopinavir/ritonavir.

@en

Electrocardiogram abnormalities with atazanavir and lopinavir/ritonavir.

@nl

P1476

Electrocardiogram abnormalities with atazanavir and lopinavir/ritonavir.

@en

P2093

Chris R Rathbun

http://www.w3.org/2001/XMLSchema#string

Donald Harrison

http://www.w3.org/2001/XMLSchema#string

Edward P Acosta

http://www.w3.org/2001/XMLSchema#string

Michelle D Liedtke

http://www.w3.org/2001/XMLSchema#string

Michelle Salvaggio

http://www.w3.org/2001/XMLSchema#string

Staci M Lockhart

http://www.w3.org/2001/XMLSchema#string

Steve M Blevins

http://www.w3.org/2001/XMLSchema#string

P2860

Atazanavir--a once-daily HIV protease inhibitor that does not cause dyslipidemia in newly treated patients: results from two randomized clinical trials.

The pharmacokinetics of HIV protease inhibitor combinations.

Combining fosamprenavir with lopinavir/ritonavir substantially reduces amprenavir and lopinavir exposure: ACTG protocol A5143 results.

Decrease of atazanavir and lopinavir plasma concentrations in a boosted double human immunodeficiency virus protease inhibitor salvage regimen

Drug interaction between amprenavir and lopinavir/ritonavir in salvage therapy.

Symptomatic orthostasis with extended-release nifedipine and protease inhibitors.

Therapy with atazanavir plus saquinavir in patients failing highly active antiretroviral therapy: a randomized comparative pilot trial.

Once-daily versus twice-daily lopinavir/ritonavir in antiretroviral-naive HIV-positive patients: a 48-week randomized clinical trial.

Electrocardiographic changes in HIV-infected, drug experienced patients treated with atazanavir.

Daily dosing of highly active antiretroviral therapy.

P304

328-336

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1310/HCT1005-328

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-09-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19906626

http://www.w3.org/2001/XMLSchema#string

P921

electrocardiography

Electrocardiogram abnormalities with atazanavir and lopinavir/ritonavir.

about

P2860

P2860

Electrocardiogram abnormalities with atazanavir and lopinavir/ritonavir.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P577

P698

P921